In the the case of Cingulate (NASDAQ:CING), which is trading at $8.2 as of publishing time, $100 would buy you 12.2 shares of stock. If you're looking to bet against a company, the process is more ...

Cingulate Inc. (NASDAQ:CING) shares are surging, trading over 159% higher today. Here’s what’s driving the movement. Why It’s Moving: Cingulate’s stock is soaring following the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

New ADHD Medication Is On Track For NDA Filing Within A Year – Hear From This Biotech's CEO What's Going On With Cingulate Shares Recently? Cingulate Inc. (NASDAQ: CING) shares are soaring Friday.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using Precision Timed Release, drug delivery platform technology to build a pipeline of next-generation pharmaceutical ...

KANSAS CITY, Kan., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery ...

KANSAS CITY, Kan., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Shane J. Schaffer, Chairman and CEO of Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed ...

Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on ...